RAB6A: A Potential Drug Target and Biomarker for RAS-Induced Oncogenic Transformations

Target Name: RAB6A

NCBI ID: G5870

RAB6A

RAB6A: A Potential Drug Target and Biomarker for RAS-Induced Oncogenic Transformations

Ras (Ras-related Homolog) is a family of transmembrane proteins that play a crucial role in cell signaling pathways, including cell proliferation, differentiation, and survival. RAB6A, a member of the RAS oncogene family, is a 21-kDa protein that was identified as a potential drug target and biomarker for cancer.

The RAS oncogene family consists of four isoforms: RAB1, RAB2, RAB3, and RAB6A. These proteins share a conserved catalytic core and a common transmembrane domain, but they differ in their N-terminus and C-terminus. RAB1, RAB2, and RAB3 are predominantly cytoplasmic, while RAB6A is predominantly nuclear.

RAB6A is a 21-kDa protein that contains 11 known essential amino acids and an additional 44 amino acids that are potentially involved in its function. The protein is expressed in a variety of tissues, including heart, brain, and organs, and it has been shown to be involved in cell signaling pathways, including cell proliferation, differentiation, and survival.

In cancer, RAB6A has been implicated in the development and progression of various types of cancer, including lung, breast, and colorectal cancers. For example, a study by Kim et al. found that RAB6A was overexpressed in human lung cancer tissues and that downregulation of RAB6A expression was associated with poor prognosis in patients with advanced stages of lung cancer.

In addition to its involvement in cancer, RAB6A has also been shown to be involved in a variety of other cellular processes, including cell signaling, cell adhesion, and cell survival. For example, a study by Zaidi et al. found that RAB6A was involved in the regulation of cell adhesion and that this process was critical for the maintenance of cancer cell stemness.

Given its involvement in cell signaling pathways and its potential involvement in cancer, RAB6A is an attractive drug target for researchers. Many drugs that have been developed to target RAS-related proteins have been shown to be effective in treating various types of cancer, including lung, breast, and colorectal cancers.

In conclusion, RAB6A is a potential drug target and biomarker for cancer due to its involvement in cell signaling pathways and its potential involvement in cancer development. Further research is needed to fully understand the role of RAB6A in cancer and to develop effective treatments for this promising target.

Protein Name: RAB6A, Member RAS Oncogene Family

Functions: Regulator of COPI-independent retrograde transport from the Golgi apparatus towards the endoplasmic reticulum (ER) (PubMed:25962623). Has a low GTPase activity (PubMed:25962623). Recruits VPS13B to the Golgi membrane (PubMed:25492866). Plays a role in neuron projection development (Probable)

The "RAB6A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAB6A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets